Back to News
Market Impact: 0.18
Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Rodman & Renshaw initiated coverage of Quince Therapeutics (NASDAQGS: QNCX) with a Buy recommendation on September 24, 2026. QNCX closed at $30.15 on September 23, unchanged from its pre-action close, indicating no reported immediate market reaction in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
QNCX0.45
More News
- Goldman’s Moe Says He’s in ‘Stronger-for-Longer Camp’ on AI
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Meta nears first new high in a year as Muse success showcases winning AI strategy
- Australia to investigate if OpenAI hack of government health website broke the law
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Document Search Enhancements, AI Enhancements, AI Actions, & Chat Export
- AI Vendor Landscape for Institutional Investment Teams